Publications

PHAR Publishes New Research on Healthcare Resource Utilization and Costs in Depression and Bipolar Disorder

Two real-world studies completed by PHAR in partnership with Otsuka Pharmaceuticals Development & Commercialization, Inc. and H. Lundbeck A/S were recently published in Advances in Therapy and the Journal of Medical Economics. Together the studies highlight potential treatment options that may reduce healthcare costs in patients with chronic mental illness. The Advances in Therapy article… read more

PHAR Publishes New Findings on Healthcare Resource Utilization and Costs in AL Amyloidosis

A study done by PHAR in partnership with Prothena Biosciences Inc., was recently published in the Journal of Comparative Effectiveness Research. The study estimated the healthcare utilization and costs in amyloid light-chain (AL) amyloidosis. The authors identified AL amyloidosis patients in claims data from 2007 to 2015 and reported inpatient hospitalizations, emergency department visits, non-ED… read more

ASCO Guidelines Developed with Methodologic Support from PHAR

On August 16, the Journal of Oncology Practice (JOP) published a joint guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) regarding high-quality palliative care as delivered as part of routine cancer care. PHAR supported the development of this important guidance by moderating a meeting of experts using the RAND/UCLA… read more

Economic Impact Study on Carcinoid Syndrome Presented at NANETS

Carcinoid syndrome describes the hormonal effects of carcinoid tumors, including the secretion of serotonin into the systemic circulation causing episodic diarrhea. Despite the frequent occurrence of this symptom, the healthcare costs and utilization associated with non-infectious diarrhea has not been elucidated. The researchers at PHAR and Novartis Pharmaceuticals Corporation presented their study on the economic… read more

Robotic vs Conventional Thyroidectomy Approaches for Thyroid Disease

Dr. Gordon Sun of PHAR, along with researchers from the University of Michigan and VA Center for Clinical Management Research compared postoperative technical, quality-of-life, and cost outcomes following either robotic or open thyroidectomy for thyroid nodules and cancer. They  examined relevant controlled trials, comparative effectiveness studies, and cohort studies for eligible publications to calculate the pooled relative risk for key postoperative… read more

Healthcare Utilization and Costs in Adults with Stable and Uncontrolled Epilepsy

Despite the availability of numerous antiepileptic drugs, some epilepsies remain resistant to treatment. We compared utilization and costs in patients with uncontrolled epilepsy to those with stable epilepsy using commercial insurance claims data.  We found patients with uncontrolled epilepsy use more services and incur higher costs compared with those with stable epilepsy. Epilepsy-related costs accounted… read more

Use of 12-gene colon cancer recurrence score assay may lead to reduction in treatment intensity

Given the small magnitude of benefit with adjuvant therapy in stage II colon cancer, chemotherapy is often selected for patients based on their physicians’ subjective assessment of clinical factors. To help guide oncologists’ adjuvant treatment recommendations for standard risk patients where other existing markers are not informative, the 12-gene colon cancer Oncotype DX® Recurrence Score®… read more

Study to Better Understand Diagnostic Practice Patterns in Head and Neck Cancer

There are no clinical guidelines on best practices for the use of bronchoscopy and esophagoscopy in diagnosing head and neck cancer.  Dr. Gordon Sun of PHAR partnered with investigators from the University of Michigan and the University of Pennsylvania to examine variation in the use of bronchoscopy and esophagoscopy across hospitals in Michigan through a… read more

Low Adherence to Dornase Alfa in Patients with Cystic Fibrosis

Patients with cystic fibrosis (CF), a common life-shortening inherited disorder, often don’t take all their medications. It has been proposed that better adherence could improve these patients’ health more than any specific medical treatment. Investigators at PHAR, LLC, in collaboration with Genentech, Inc. conducted a retrospective cohort analysis and confirmed that there was generally low… read more

Hematologic Conditions in Patients with Myelodysplastic Syndrome

PHAR researchers collaborated with investigators at Eisai Inc. to evaluate the prevalence of hematologic conditions in patients with myelodysplastic syndrome (MDS). Researchers compared two MDS patient groups: patients receiving hypomethylating agents (HMAs) and patients receiving supportive care alone. The study concluded that hematologic conditions were more common in patients who received HMAs, with the most… read more